quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:00:00·32d
PRRelease
HUTCHMED (China) Limited logo

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HCM· HUTCHMED (China) Limited
Health Care
Original source

Companies

  • HCM
    HUTCHMED (China) Limited
    Health Care

Recent analyst ratings

  • Sep 22UpdateMorgan Stanley$13.75
  • May 13UpdateHSBC Securities-
  • Nov 24UpdateDeutsche Bank-
  • May 4UpdateDeutsche Bank-
  • Sep 22UpdateGoldman$46.00
  • Aug 3UpdateJefferies$52.00

Related

  • PR17h
    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026
  • SEC14d
    SEC Form 6-K filed by HUTCHMED (China) Limited
  • SEC14d
    SEC Form 6-K filed by HUTCHMED (China) Limited
  • PR15d
    HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
  • INSIDER23d
    SEC Form 3 filed by new insider Nixon Charles George Rupert
  • SEC31d
    SEC Form 6-K filed by HUTCHMED (China) Limited
  • INSIDER36d
    SEC Form 3 filed by new insider Chiu Lorenso
  • INSIDER38d
    New insider Su Wei-Guo claimed ownership of 3,563,905 units of ordinary shares and claimed ownership of 237,063 units of American depositary shares (SEC Form 3)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022